Cancer cells consume iron at rates far beyond what normal cells require, and they actively rewire their internal machinery to grab more of it. That much is well established. But the question of whether iron “feeds” cancer is more layered than a simple yes or no, because the same metal that fuels tumor growth also turns out to be a vulnerability that researchers are learning to exploit. The relationship between iron and cancer runs through cell biology, diet, the immune system, and some of the most promising experimental therapies in oncology.
Why Cancer Cells Are Hungry for Iron
Every cell in your body needs iron. It is essential for DNA replication, energy production, and building new proteins. But cancer cells, because they divide so rapidly, need a lot more of it. Iron gets incorporated into enzymes like ribonucleotide reductase, which is required for making the building blocks of DNA. Without enough iron, a cell cannot copy its genome, and without copying its genome, it cannot divide.1Applied Sciences. The Role of Iron in DNA and Genomic Instability in Cancer, a Target for Iron Chelators That Can Induce ROS Cancer cells have essentially the same metabolic needs as normal cells, just amplified by their relentless growth.
To meet that demand, tumors don’t passively wait for iron to drift their way. They change the proteins on their surface to pull in more of it. One of the most consistent findings across solid tumors is the overexpression of transferrin receptor 1 (TfR1), the main gateway for iron entry into cells. When cancer cells ramp up production of this receptor, they can capture more transferrin, the iron-carrying protein in blood, than surrounding healthy tissue. This overexpression has been linked to worse treatment outcomes across multiple cancer types.2PubMed Central. Transferrin Receptor Overexpression in Solid Tumors Is Associated with Inflamed Microenvironments and Upregulated Immune Checkpoints, with Implications for Immunotherapy Sensitivity
At the same time, cancer cells often reduce expression of ferroportin, the only known protein that exports iron out of a cell. In multiple myeloma cells, for example, knocking out ferroportin led to higher intracellular iron levels, which in turn promoted proliferation.3PubMed Central. Ferroportin downregulation promotes cell proliferation by modulating the Nrf2–miR-17-5p axis in multiple myeloma The result is a cell that hoovers up iron on one end and blocks its exit on the other. Meanwhile, tumors can also stockpile iron inside ferritin, the cell’s iron-storage protein. In acute myeloid leukemia, both heavy and light chains of ferritin are overexpressed in leukemic stem cells compared with normal blood-forming stem cells.4PubMed. Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia
How Tumors Hijack the Immune System’s Iron Supply
Cancer cells don’t just change themselves to acquire more iron. They also co-opt nearby immune cells into becoming iron suppliers. Macrophages, a type of white blood cell, normally play a dual role in iron handling depending on their activation state. When macrophages are in an inflammatory, infection-fighting mode, they hoard iron and lock it away in ferritin to starve pathogens. But when they shift to a wound-healing, anti-inflammatory state, they start releasing iron into the surrounding tissue through ferroportin and other pathways.5PubMed Central. The Iron Curtain: Macrophages at the Interface of Systemic and Microenvironmental Iron Metabolism and Immune Response in Cancer
Tumors are skilled at pushing macrophages toward that iron-releasing state. In breast cancer, tumor-associated macrophages secrete iron bound to a protein called lipocalin-2, essentially packaging iron and handing it to the tumor. Research using a mouse model of spontaneous breast cancer found that macrophage expression of lipocalin-2 in the tissue surrounding the tumor correlated with earlier tumor onset, more lung metastases, and higher rates of recurrence. Interestingly, ferroportin expression on those same macrophages did not show the same correlation, suggesting that the lipocalin-2 pathway is a more important iron delivery route in this context.6PubMed Central. Iron-Bound Lipocalin-2 from Tumor-Associated Macrophages Drives Breast Cancer Progression Independent of Ferroportin
Tumors can also manipulate iron at the whole-body level. Hepcidin, the master hormone that regulates how much iron enters the bloodstream from the gut and from macrophages, is often dysregulated in cancer. When tumors drive hepcidin levels up, ferroportin on other cells gets degraded, trapping iron inside tumor tissue and reducing the iron available to the rest of the body. This helps explain why many cancer patients develop anemia even when their total body iron stores are adequate: the iron is being redirected, not absent.7PubMed Central. Distinctive modulation of hepcidin in cancer and its therapeutic relevance
Dietary Heme Iron and Colorectal Cancer
The relationship between iron in your diet and cancer risk has been studied most thoroughly for colorectal cancer, and the evidence is real but nuanced. The concern centers on heme iron, the form found in red meat and processed meat, rather than non-heme iron from plants and supplements. A meta-analysis pooling data from prospective studies covering more than half a million people found that those with the highest heme iron intake had about an 18% greater risk of colon cancer compared with the lowest intake group.8PubMed. Heme iron from meat and risk of colorectal cancer: a meta-analysis and a review of the mechanisms involved
The picture is not perfectly clean, though. A large European cohort study found the heme iron association was weaker and not statistically significant after adjustment, particularly in women, where no link was seen at all. In men, substituting non-heme iron for heme iron was associated with modestly lower colorectal cancer risk.9British Journal of Cancer. Dietary intake of total, heme and non-heme iron and the risk of colorectal cancer in a European prospective cohort study So the signal exists, but it is not as strong or uniform as headlines sometimes suggest.
What makes heme iron specifically concerning is the type of DNA damage it appears to cause. A Dutch cohort study found that high heme iron intake was associated with colorectal tumors carrying specific types of mutations, particularly G-to-A transitions in the KRAS and APC genes. These are alkylating-type mutations, not the oxidative damage that most people associate with iron’s harmful effects. The highest intake group had roughly 70–80% greater risk of tumors harboring these specific mutation patterns compared with the lowest intake group.10Carcinogenesis. Dietary heme iron and the risk of colorectal cancer with specific mutations in KRAS and APC This finding matters because it points to a mechanism beyond generic oxidative stress and suggests heme iron may promote cancer through chemical pathways specific to its molecular structure.
Iron Overload Disorders and Liver Cancer
The most dramatic evidence that excess iron can drive cancer comes from hereditary hemochromatosis, a genetic condition that causes the body to absorb far too much iron from food. Over decades, iron accumulates in the liver, heart, and other organs. A large Scandinavian study found that patients with hemochromatosis had a roughly 20-fold increased risk of liver cancer compared with the general population. At ten years of follow-up, about 6% of men and 1.5% of women with the condition had developed liver cancer.11PubMed. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives Reassuringly, the risk of cancers outside the liver was only slightly elevated.
The link between hepatic iron overload and liver cancer is now well recognized, and hemochromatosis was the first condition where this connection was firmly established.12PubMed Central. Hepatic Iron Overload and Hepatocellular Carcinoma The liver is uniquely vulnerable because it is the primary site of iron storage and the first organ to bear the burden when systemic iron regulation fails. But this risk is specific to chronic, severe iron overload in the liver itself, not to having slightly elevated iron levels from a steak dinner. The distinction is worth keeping in mind when evaluating claims about dietary iron.
Iron’s Role in Helping Tumors Spread
Beyond fueling raw growth, excess iron may help cancer cells become more invasive. When cells transition from a stationary, tissue-bound state to a mobile, invasive one, biologists call this epithelial-to-mesenchymal transition, or EMT. It is a process that normally occurs during wound healing and embryonic development but gets hijacked by cancer cells that want to break away from a primary tumor and spread elsewhere.
Laboratory experiments have shown that exposing liver cancer cells to excess iron elevates markers of this mesenchymal, migratory state, including increased levels of proteins like N-cadherin and vimentin. Researchers found this effect was partially mediated through changes in specific transcription factors, and the shift happened through mechanisms distinct from simple oxidative damage.13Scientific Reports. Iron elevates mesenchymal and metastatic biomarkers in HepG2 cells In pancreatic cells, prolonged exposure to excess iron pushed normal epithelial cells toward a mesenchymal phenotype, and cancer cells that had already started down the path became even more invasive.14Asian Journal of Pharmaceutical Sciences. Chronic exposure to excess iron promotes EMT and cancer via p53 loss in pancreatic cancer These findings are from cell culture and animal work, so we should be cautious about applying them directly to people, but they fit with the broader picture: iron does not just help tumors grow in place, it may also help them travel.
Cancer Stem Cells Have Even Higher Iron Demands
Not all cells in a tumor are equal. A small subpopulation known as cancer stem cells is thought to drive tumor initiation, drug resistance, and recurrence after treatment. These cells accumulate even more iron than the already iron-hungry bulk tumor population. Their iron uptake, storage, and export machinery all skew toward maximizing intracellular iron.15PubMed Central. Regulation of iron metabolism and ferroptosis in cancer stem cells
This extreme iron dependence is both a problem and a potential opportunity. It helps explain why cancer stem cells are so resilient: they stockpile the resources they need for rapid division and survival in hostile conditions. But it also means they may be especially vulnerable to therapies that disrupt iron metabolism. If you can cut off the iron supply or weaponize the iron already inside the cell, these hard-to-kill cells might be more susceptible than the run-of-the-mill tumor cells around them.
The Other Edge of the Sword: Ferroptosis
Here is where the story flips. The same iron that fuels cancer growth can also destroy cancer cells through a form of cell death called ferroptosis. In ferroptosis, iron inside the cell drives chemical reactions that tear apart the fats in cell membranes. Specifically, iron catalyzes the production of reactive oxygen species that attack polyunsaturated fatty acids in the membrane, creating lipid peroxides. If the cell’s defenses against lipid peroxidation fail, the membrane disintegrates and the cell dies.
Cancer cells maintain a pool of loosely bound, reactive iron inside them, known as the labile iron pool. Researchers have found that this pool is typically larger in tumor cells than in healthy cells, and they have developed strategies to exploit it. One approach uses compounds called hydroperoxides that are normally nontoxic but become lethal when they encounter the elevated labile iron pool inside cancer cells. The labile iron triggers a Fenton-type chemical reaction that converts these benign molecules into cell-killing free radicals, selectively in tumor tissue.16PubMed. Endogenous Labile Iron Pool-Mediated Free Radical Generation for Cancer Chemodynamic Therapy
Ferroptosis is not just an interesting lab phenomenon. It is increasingly seen as a way to overcome drug resistance. Tumors that have stopped responding to conventional chemotherapy can sometimes be killed by triggering ferroptosis through a different pathway entirely. Three main routes have been identified: disrupting the cell’s primary lipid-peroxide defense system, manipulating iron metabolism directly, and altering lipid composition to make membranes more vulnerable.17PubMed Central. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance Growing evidence supports the idea that drugs that induce ferroptosis could overcome resistance in tumors that have become insensitive to standard treatments.18PubMed. Overcoming cancer chemotherapy resistance by the induction of ferroptosis
Artemisinin derivatives, originally developed as antimalarial drugs, are one class of compounds that have been shown to kill tumor cells through ferroptosis. In lab experiments, ferrostatin-1 (a ferroptosis inhibitor) and deferoxamine (an iron chelator) both significantly reduced the cancer-killing activity of one such derivative, confirming that the mechanism depends on iron-driven lipid peroxidation.19PubMed. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells
The Immune System Complication
Ferroptosis is not a free lunch. The immune system also has iron-sensitive cells, and triggering ferroptosis indiscriminately could harm anti-tumor immunity. Regulatory T cells, which normally suppress excessive immune responses, rely on an enzyme called GPX4 to protect themselves from lipid peroxidation during activation. When GPX4 is knocked out in these cells, they accumulate lipid peroxides and die by ferroptosis. Iron chelators rescued these cells from death, confirming that iron is the driving force behind the vulnerability.20Cell Reports. Glutathione peroxidase 4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation
This creates a tricky balancing act for therapy design. You want to induce ferroptosis in tumor cells while sparing immune cells that are trying to fight the tumor. The elevated labile iron pool in cancer cells offers some degree of natural selectivity, but it is not a sharp line. Getting this right is one of the central challenges in translating ferroptosis research from the lab to the clinic.
Therapeutic Approaches That Target Iron
Researchers are pursuing iron-related cancer therapies from two opposite directions at once: starving tumors of iron and weaponizing the iron already inside them.
On the starvation side, iron chelators are drugs that bind to iron and remove it from circulation or from inside cells. Experimental chelators have shown potent anti-cancer properties in laboratory studies. Deferasirox, a chelator already approved for treating iron overload in transfusion-dependent patients, has demonstrated anti-tumor effects in cell and animal models.21PubMed. Iron chelation in the treatment of cancer: a new role for deferasirox? The anti-cancer effect of chelation works partly by inhibiting ribonucleotide reductase, the iron-dependent enzyme needed for DNA synthesis, and partly because some chelator-iron complexes are themselves chemically reactive and generate damaging free radicals.22PubMed. Iron chelators in cancer therapy So even in the “starvation” approach, iron’s destructive potential plays a role.
On the weaponization side, superparamagnetic iron oxide nanoparticles, often called SPIONs, are being developed as multifunctional cancer-fighting tools. These tiny particles can be loaded with chemotherapy drugs, guided to tumors using external magnets, and used for both magnetic resonance imaging and localized heat therapy. They combine targeted drug delivery with real-time imaging and magnetic heating in a single platform.23PubMed. Targeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy Researchers have created nanoparticles loaded simultaneously with a chemotherapy drug and iron oxide crystals, enabling tumor-targeted imaging, drug delivery, and monitoring of treatment response all at once.24PubMed. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy In these approaches, iron is not the enemy. It is the weapon.
Your Gut Microbiome May Determine Whether Dietary Iron Promotes Cancer
One of the more surprising recent findings is that whether oral iron supplements promote colorectal cancer may depend on the bacteria already living in your gut. A 2025 mouse study gave oral iron supplements to animals that had been colonized with gut bacteria from either colorectal cancer patients or healthy donors. Iron supplementation significantly increased tumor count, tumor size, and the incidence of advanced tumors, but only in mice carrying the cancer-patient microbiome. Mice with the healthy-donor microbiome showed no such effect.25BioMed Central. Initial gut microbiota composition is a determining factor in the promotion of colorectal cancer by oral iron supplementation: evidence from a murine model
This is a single animal study, so it is too early to change clinical practice based on it alone. But it raises a provocative possibility: the risk of iron supplementation may not be uniform across people. If your gut microbiome is already shifted toward a cancer-promoting composition, supplemental iron could act as fuel for the wrong bacteria or the wrong biochemical pathways. For the many cancer patients who receive iron supplements to treat anemia, and for the general public taking iron for various reasons, the microbiome dimension adds a layer of personalization that the field is only beginning to understand. Clinicians already weigh the benefits of correcting anemia against theoretical iron-related risks in cancer patients; findings like these may eventually help sharpen that calculation by identifying who is most vulnerable.